Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models()()()

INTRODUCTION: The rarity of dedifferentiated liposarcoma (DDLPS) and the lack of experimental DDLPS models limit the development of novel therapeutic strategies. Pazopanib (PAZ) is a tyrosine kinase inhibitor that is approved for the treatment of non-adipocytic advanced soft tissue sarcoma. The acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Haifu, Wozniak, Agnieszka, Sciot, Raf, Cornillie, Jasmien, Wellens, Jasmien, Van Looy, Thomas, Vanleeuw, Ulla, Stas, Marguerite, Hompes, Daphne, Debiec-Rychter, Maria, Schöffski, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311036/
https://www.ncbi.nlm.nih.gov/pubmed/25500074
http://dx.doi.org/10.1016/j.tranon.2014.09.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311036/
https://www.ncbi.nlm.nih.gov/pubmed/25500074
http://dx.doi.org/10.1016/j.tranon.2014.09.007

Ejemplares similares